Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
Authors:
Open Access
- 1 September 2009
- journal article
- review article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 5, 793-9
Abstract
Peer reviewed article authored by (Rakesh K Sharma, Vibhuti N Singh, Hanumanth K Reddy). Read article or submit your manuscript for publishing.Keywords
This publication has 58 references indexed in Scilit:
- Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non–HDL Cholesterol (from the SEACOAST I Study)The American Journal of Cardiology, 2008
- Lipoprotein Management in Patients With Cardiometabolic RiskJACC, 2008
- Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trialThe Lancet, 2007
- Safety Considerations with Omega-3 Fatty Acid TherapyThe American Journal of Cardiology, 2007
- Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in HumansThe Journal of Clinical Pharmacology, 2004
- Niacin and cholesterol: role in cardiovascular disease (review)The Journal of Nutritional Biochemistry, 2003
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Atherosclerosis: Basic MechanismsCirculation, 1995